Chemotherapy (investigator's choice)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Chemotherapy (investigator's choice), covering 2026-01-27 to 2026-01-27. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) [Phase 3]